Kiromic Biopharma, Inc. Contracts & Agreements

Form of Exchange Agreement dated as of November 1, 2024 between the Company and the holder of the Exchange Notes (Filed With SEC on November 4, 2024)

Form of Exchange Agreement dated as of September 27, 2024 between the Company and the holder of the Exchange Securities (Filed With SEC on September 30, 2024)

Executive Employment Agreement Amendment dated as of August 7, 2024 by and between Kiromic Biopharma, Inc. and Brian Hungerford (Filed With SEC on August 9, 2024)

25% Senior Secured Convertible Promissory Note, dated August 1, 2024 (Filed With SEC on August 5, 2024)

25% Senior Secured Convertible Promissory Note (Filed With SEC on July 10, 2024)

First Amendment to 25% Senior Secured Convertible Promissory Note (Filed With SEC on July 10, 2024)

Exchange Agreement dated as of June 21, 2024 between the Company and the Holder (Filed With SEC on June 27, 2024)

25% Senior Secured Convertible Promissory Note (Filed With SEC on June 27, 2024)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on June 7, 2024)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on May 6, 2024)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on April 5, 2024)

Form of Exchange Agreement dated as of March 28, 2024 between the Company and the holder of the Exchange Securities (Filed With SEC on April 2, 2024)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on March 11, 2024)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on February 14, 2024)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on January 11, 2024)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on December 15, 2023)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on November 6, 2023)

Executive Employment Agreement dated as of October 1, 2023 by and between Kiromic Biopharma, Inc. and Brian Hungerford (Filed With SEC on October 3, 2023)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on October 2, 2023)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on August 29, 2023)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on July 27, 2023)

Form of Exchange Agreement dated as of July 18, 2023 between the Company and the holder of the Exchange Securities (Filed With SEC on July 19, 2023)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on June 27, 2023)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on May 30, 2023)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on April 28, 2023)

Form of Exchange Agreement dated as of March 28, 2023 between the Company and the holder of the Exchange Securities (Filed With SEC on March 31, 2023)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on March 31, 2023)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on February 27, 2023)

Form of Note Purchase Agreement (Filed With SEC on January 26, 2023)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on January 26, 2023)

Separation Agreement between Daniel Clark and Kiromic BioPharma, Inc. dated December 27, 2022 (Filed With SEC on December 30, 2022)

Form of the Amended and Restated 25% Senior Secured Convertible Promissory Note (Filed With SEC on December 16, 2022)

Amended Stipulation of Settlement and Mutual Release, dated October 27, 2022, by and among Kiromic Biopharma, Inc., Empery Asset Master, Ltd. and other parties (Filed With SEC on November 2, 2022)

Amended Stipulation of Settlement and Mutual Release, dated October 27, 2022, by and among Kiromic Biopharma, Inc., Sabby Volatility Warrant Master Fund Ltd. and other parties (Filed With SEC on November 2, 2022)

Form of the 25% Senior Secured Convertible Promissory Note (Filed With SEC on October 27, 2022)

Standby Equity Purchase Agreement, dated October 13, 2022, by and between Kiromic Biopharma, Inc. and YA II PN, Ltd (Filed With SEC on October 19, 2022)

Stipulation of Settlement and Mutual Release, dated October 10, 2022, by and among Kiromic Biopharma, Inc., Empery Asset Master, Ltd. and other parties (Filed With SEC on October 14, 2022)

Stipulation of Settlement and Mutual Release, dated October 10, 2022, by and among Kiromic Biopharma, Inc., Sabby Volatility Warrant Master Fund Ltd. and other parties (Filed With SEC on October 14, 2022)

Form of the Subordinated Convertible Promissory Note (Filed With SEC on October 14, 2022)

Form of Underwriting Agreement (Filed With SEC on July 13, 2022)

Form of Common Stock Warrants (Filed With SEC on July 13, 2022)

Form of Warrant Agent Agreement (Filed With SEC on July 13, 2022)

Form of Pre-Funded Warrant (Filed With SEC on July 13, 2022)

Form of Representatives Warrant (Filed With SEC on July 13, 2022)

Executive Employment Agreement effective as of July 11, 2022, by and between Kiromic BioPharma, Inc. and Dr. Leonardo Mirandola (Filed With SEC on July 12, 2022)

Form of Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement (Filed With SEC on June 27, 2022)

First Amendment to Executive Employment Agreement effective as of May 10, 2022, by and between Kiromic BioPharma, Inc. and Pietro Bersani (Filed With SEC on May 11, 2022)

First Amendment to Executive Employment Agreement effective as of May 10, 2022, by and between Kiromic BioPharma, Inc. and Daniel Clark (Filed With SEC on May 11, 2022)

Description of Securities (Filed With SEC on April 8, 2022)

Transition and Consulting Agreement effective as of February 9, 2022, by and between Kiromic BioPharma, Inc. and Gianluca Rotino (Filed With SEC on February 16, 2022)

Modification to Employment Agreement effective as of February 9, 2022, by and between Kiromic BioPharma, Inc. and Scott Dahlbeck (Filed With SEC on February 16, 2022)

Executive Employment Agreement effective as of February 14, 2022, by and between Kiromic BioPharma, Inc. and Daniel Clark (Filed With SEC on February 16, 2022)

Confidential Information, Inventions, Non-Solicitation, and Non-Competition Agreement effective as of February 14, 2022, between Kiromic BioPharma, Inc. and Daniel Clark (Filed With SEC on February 16, 2022)

Indemnification Agreement effective as of February 14, 2022, by and between Kiromic BioPharma, Inc. and Daniel Clark (Filed With SEC on February 16, 2022)

Executive Employment Agreement effective as of January 27, 2022 by and between Kiromic BioPharma, Inc. and Pietro Bersani (Filed With SEC on February 2, 2022)

Confidential Information, Inventions, Non-Solicitation, and Non-Competition Agreement effective as of January 27, 2022 between Kiromic BioPharma, Inc. and Pietro Bersani (Filed With SEC on February 2, 2022)

Indemnification Agreement effective as of January 27, 2022 by and between Kiromic BioPharma, Inc. and Pietro Bersani (Filed With SEC on February 2, 2022)

Separation Agreement dated as of December 6, 2021 between Kiromic Biopharma, Inc. and Ignacio Nunez (Filed With SEC on December 10, 2021)

Executive Employment Agreement by and between the Company and Dr. Michael Ryan, effective as of July 1, 2021 (Filed With SEC on July 8, 2021)

Form of Underwriting Agreement (Filed With SEC on June 25, 2021)

Form of Representatives Warrant (Filed With SEC on June 25, 2021)

Fifth Amendment to Lease Agreement, dated December 2, 2020, between Cambridge Properties and Kiromic BioPharma, Inc (Filed With SEC on June 25, 2021)

Sixth Amendment to Lease Agreement, dated March 22, 2021, between Cambridge Properties and Kiromic BioPharma, Inc (Filed With SEC on June 25, 2021)

Membership Interest Purchase Agreement dated as of June 14, 2021 among Kiromic BioPharma, Inc., In Silico Solution, LLC and Michael Ryan (Filed With SEC on June 17, 2021)

Executive Employment Agreement by and between the Company and Mr. Ignacio Nunez, effective as of June 7, 2021 (Filed With SEC on June 7, 2021)

Letter of Intent, dated April 8, 2021 (Filed With SEC on April 13, 2021)

Description of Securities (Filed With SEC on March 31, 2021)

Strategic Alliance Agreement by and between the Company and Leon Office (H.K.) Ltd, effective as of January 28, 2021 (Filed With SEC on February 12, 2021)

Amended and Restated License Agreement by and between the Company and Longwood University, dated as of November 30, 2020 (Filed With SEC on January 29, 2021)

Form of Representatives Warrant Agreement (Filed With SEC on November 30, 2020)

Underwriting Agreement, dated October 15, 2020 (Filed With SEC on October 21, 2020)

Form of Underwriting Agreement (Filed With SEC on July 13, 2020)

Form of Representatives Warrant (Filed With SEC on July 13, 2020)

Employment Agreement, to be effective upon the initial public offering, between Kiromic BioPharma, Inc. and Tony Tontat (Filed With SEC on June 26, 2020)

Employment Agreement dated January 1, 2020 between Kiromic BioPharma, Inc and Scott Dahlbeck (Filed With SEC on June 26, 2020)

Employment Agreement, to be effective upon the initial public offering, between Kiromic BioPharma, Inc. and Gianluca Rotino (Filed With SEC on June 26, 2020)

Employment Agreement, to be effective upon the initial public offering, between Kiromic BioPharma, Inc. and Maurizio Chiriva Internati (Filed With SEC on June 26, 2020)

Form of Director Services Agreement, to be effective upon initial public offering, between Kiromic BioPharma, Inc. and all independent directors (Filed With SEC on June 26, 2020)

Form of Director Indemnification Agreement, to be effective upon initial public offering, between Kiromic BioPharma, Inc. and all independent directors (Filed With SEC on June 26, 2020)

Form of Warrant to Purchase Common Stock (Filed With SEC on May 11, 2020)

Series B Preferred Stock Purchase Agreement, dated September 7, 2019, among Kiromic BioPharma, Inc. and certain investors (Filed With SEC on May 11, 2020)

Investors Rights Agreement, dated September 7, 2019, among Kiromic BioPharma, Inc. and certain investors (Filed With SEC on May 11, 2020)

Right of First Refusal and Co-Sale Agreement, dated September 7, 2019, among Kiromic BioPharma, Inc., certain investors and certain stockholders (Filed With SEC on May 11, 2020)

Voting Agreement, dated September 7, 2019, among Kiromic BioPharma, Inc., certain investors and certain stockholders (Filed With SEC on May 11, 2020)

Form of Securities Purchase Agreement for Series A-1 Preferred Stock (Filed With SEC on May 11, 2020)

Convertible Promissory Note issued by Kiromic BioPharma, Inc. to Prevail Partners on May 30, 2019 (Filed With SEC on May 11, 2020)

Form of 17% Convertible Promissory Note issued by Kiromic BioPharma, Inc. to certain investors (Filed With SEC on May 11, 2020)

Form of 7% Convertible Promissory Note issued by Kiromic BioPharma, Inc. to certain investors (Filed With SEC on May 11, 2020)

Stockholders Agreement, dated May 27, 2016, among Kiromic BioPharma, Inc. and certain stockholders (Filed With SEC on May 11, 2020)

License Agreement, dated December 1, 2016, between Mercer University and Kiromic BioPharma, Inc (Filed With SEC on May 11, 2020)

License Agreement, dated September 14, 2018, between CGA 369 Intellectual Holdings, Inc. and Kiromic BioPharma, Inc (Filed With SEC on May 11, 2020)

Amendment to License Agreement, dated October 16, 2019, between CGA 369 Intellectual Holdings, Inc. and Kiromic BioPharma, Inc (Filed With SEC on May 11, 2020)

Collaboration Agreement, dated February 4, 2019, between University of Texas MD Anderson Cancer Center and Kiromic BioPharma, Inc (Filed With SEC on May 11, 2020)

Collaboration Agreement, dated February 6, 2020, between University of Texas MD Anderson Cancer Center and Kiromic BioPharma, Inc (Filed With SEC on May 11, 2020)

Lease Agreement, dated October 9, 2015, between Timothy L. Sharma d/b/a Cambridge Properties and Kiromic, Inc (Filed With SEC on May 11, 2020)

Second Amendment to Lease Agreement, dated May 6, 2016, between Cambridge Properties and Kiromic, Inc (Filed With SEC on May 11, 2020)

Third Amendment to Lease Agreement, dated November 7, 2018, between Cambridge Properties and Kiromic, Inc (Filed With SEC on May 11, 2020)

Fourth Amendment to Lease Agreement, dated October 8, 2019, between Cambridge Properties and Kiromic, Inc (Filed With SEC on May 11, 2020)

Employment Agreement, dated March 20, 2016, between Kiromic, Inc. and Maurizio Chiriva Internati (Filed With SEC on May 11, 2020)

Addendum to Employment Agreement, dated March 20, 2016, between Kiromic, Inc. and Maurizio Chiriva Internati (Filed With SEC on May 11, 2020)

Consulting Agreement, dated November 2, 2018, between Kiromic, Inc. and Scott Dahlbeck (Filed With SEC on May 11, 2020)

Addendum to Consulting Agreement, dated August 1, 2019, between Kiromic, Inc. and Scott Dahlbeck (Filed With SEC on May 11, 2020)

Consulting Agreement, dated July 20, 2018, between Kiromic, Inc. and Gianluca Rotino (Filed With SEC on May 11, 2020)

Addendum to Consulting Agreement, dated August 1, 2019, between Kiromic, Inc. and Gianluca Rotino (Filed With SEC on May 11, 2020)

Kiromic, Inc. 2017 Equity Incentive Plan (Filed With SEC on May 11, 2020)

Joint venture agreement, dated 4.06.2020, between Molipharma S.R.L. and Kiromic BioPharma, Inc (Filed With SEC on May 11, 2020)

Category

Industry

Companies

Contracts

Kiromic Biopharma, Inc. Contracts & Agreements